- Active, not recruiting
NCT04045795: Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04045795: Phase 1: Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04045795: Phase 1: Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
To evaluate the safety and tolerability of isatuximab administered subcutaneously (SC) versus intravenously (IV)
To assess the safety and tolerability (including local injection site tolerability) of isatuximab using the (investigational) isatuximab injector device.
To evaluate the pharmacokinetics (PK) of SC and IV isatuximab
Sponsor
ClinicalTrials.gov Identifier: NCT05405166
Official Title: A Multi-center, Open-label, Phase 1b Study to Assess the Pharmacokinetics, Safety, and Efficacy of Subcutaneous and Intravenous Isatuximab (SAR650984) in Combination With Pomalidomide and Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
First Posted : August 6, 2019
Click here to see details on ClinicalTrials.gov
Isatuximab : National Cancer Institute
Isatuximab : MedlinePlus Drug Information
Dexamethasone : National Cancer Institute
Dexamethasone : MedlinePlus Drug Information
Pomalidomide : National Cancer Institute